280 related articles for article (PubMed ID: 22529231)
41. Primary prevention cardiovascular disease: better than drugs.
Pippin JJ
Arch Intern Med; 2010 Nov; 170(20):1860-1; author reply 1861. PubMed ID: 21059984
[No Abstract] [Full Text] [Related]
42. [Statin cuts cardiovascular risk in half].
Einecke D
MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
[No Abstract] [Full Text] [Related]
43. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Robinson JG; Davidson MH
Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):461-76. PubMed ID: 16918265
[TBL] [Abstract][Full Text] [Related]
44. Statin therapy with ezetimibe or niacin in high-risk patients.
Kastelein JJ; Bots ML
N Engl J Med; 2009 Nov; 361(22):2180-3. PubMed ID: 19915218
[No Abstract] [Full Text] [Related]
45. Cost and effectiveness of cardiovascular prevention.
Boyar A
Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
[No Abstract] [Full Text] [Related]
46. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Katsiki N; Athyros VG; Karagiannis A; Mikhailidis DP
Int Angiol; 2011 Jun; 30(3):295; author reply 296. PubMed ID: 21617615
[No Abstract] [Full Text] [Related]
47. ["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].
Olsson AG; Nilsson PM
Lakartidningen; 2009 Mar 18-24; 106(12):854-7. PubMed ID: 19452786
[No Abstract] [Full Text] [Related]
48. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Moyad MA; Merrick GS
Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
[TBL] [Abstract][Full Text] [Related]
49. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
Colhoun H
Lancet; 2005 Nov; 366(9500):1829-31. PubMed ID: 16310536
[No Abstract] [Full Text] [Related]
50. [Guideline for management of lipid metabolism].
Ishibashi S
Nihon Rinsho; 2002 Sep; 60 Suppl 9():675-8. PubMed ID: 12387068
[No Abstract] [Full Text] [Related]
51. [Statins in primary prevention - a must for the general practitioner?].
Zoller M
Praxis (Bern 1994); 2011 Jul; 100(14):859-60. PubMed ID: 21732299
[No Abstract] [Full Text] [Related]
52. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
Farmer JA
Am J Cardiol; 1998 Sep; 82(6A):26M-31M. PubMed ID: 9766345
[TBL] [Abstract][Full Text] [Related]
53. ARBITER 6-HALTS. Does it have the power to settle all matters?
Ferrario CM
Ther Adv Cardiovasc Dis; 2010 Apr; 4(2):77-81. PubMed ID: 20360390
[No Abstract] [Full Text] [Related]
54. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R;
Lancet; 2005 May 21-27; 365(9473):1779-85. PubMed ID: 15910950
[TBL] [Abstract][Full Text] [Related]
55. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
Jackson JD
Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
[No Abstract] [Full Text] [Related]
56. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.
Michailov GV; Davies GM; Krobot KJ
Eur J Health Econ; 2012 Jun; 13(3):365-74. PubMed ID: 21465286
[TBL] [Abstract][Full Text] [Related]
57. Do patients on statins also need niacin?
Jones KW
JAAPA; 2013 Jul; 26(7):9-10. PubMed ID: 23923280
[TBL] [Abstract][Full Text] [Related]
58. Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.
Kent S; Haynes R; Hopewell JC; Parish S; Gray A; Landray MJ; Collins R; Armitage J; Mihaylova B;
Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):348-54. PubMed ID: 27407053
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases.
Corrao G; Scotti L; Zambon A; Baio G; Nicotra F; Conti V; Capri S; Tragni E; Merlino L; Catapano AL; Mancia G
Atherosclerosis; 2011 Aug; 217(2):479-85. PubMed ID: 21592477
[TBL] [Abstract][Full Text] [Related]
60. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.
Arrieta A; Page TF; Veledar E; Nasir K
PLoS One; 2017; 12(1):e0169761. PubMed ID: 28081164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
